# The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

> **NCT05075512** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **DRUG:** anlotinib, fulvestrant

## Key facts

- **NCT ID:** NCT05075512
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075512, "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05075512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*